Effectiveness of doxifluridine (5′-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens

Gastric Cancer

Volumn 5, Issue 4, 2002, Pages 233-236

  Sato, Atsushi ^a   Shimada, Ken ^a   Nakamachi, Masatoshi ^a   Ushio, Jun ^a   Yamamoto, Wataru ^a   Kurihara, Minoru ^a   Matsukawa, Masaaki ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination chemotherapy; Docetaxel; Doxifluridine; Gastric cancer; Multidrug resistance

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; UFT;

ADULT; ANTINEOPLASTIC ACTIVITY; AORTA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CASE REPORT; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; GASTRECTOMY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; SPLENECTOMY; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; SURGICAL TECHNIQUE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FLOXURIDINE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS;

EID: 0037512492     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101200200040     Document Type: Article

References (19)

1. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English Ed. Tokyo: Kanehara; 1995. pp. 4-5.
2. Sato A, Kurihara M, Koizumi W, Takeda Y, Fukuyama A. Phase II study of UFT plus cisplatin (UFTP) therapy in patients with advanced gastric cancer. Proc ASCO 2000;19:279.
3. Sato A, Kurihara M, Matsukawa M, Shimada K, Yamazaki T, Koda T, et al. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 2001;47: 380-84.
4. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
5. Sasaki T, Oota K, Ihayashi J, Sakata Y, Matsuoka T, Sakai Y, et al. A randomised clinical trial of combination chemotherapy of methotrexate and 5-FU, and a monotherapy of 5-FU for gastric cancer. Methotrexate/5-FU Sequential Chemotherapy Cooperative Phase III study. Jpn J Cancer Chemother 1989;16:2545-55.
6. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English Ed. Tokyo: Kanehara; 1995. pp. 90-100.
7. National Cancer Institute. Common toxicity criteria. Version 2.0. 1998.
8. Ishitsuka H, Miwa M, Maruyama HB, Takemoto K, Fukuoka K, Itogo A, et al. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980;71:112-23.
9. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Ishitsuka H, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
10. Niitani H, Kimura K, Saito T, jj et al. Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer. Multi-institutional cooperative study. Jpn J Cancer Chemother 1985;12:2044-51.
11. Noda K, Terajima Y, Ogita Y, et al. Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri. Jpn J Cancer Chemother 1994;21:2471-7.
12. Kudo S, Hino M, Fujita A, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer. Jpn J Cancer Chemother 1994;21:2617-23.
13. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer. Jpn J Cancer Chemother 1994;21:2625-32.
14. Onoshi T, Watanabe K, Furuse K, et al. Late phase II trial of RP56976 (docetaxel) in patients with non-small-cell lung cancer. Jpn J Cancer Chemother 1995;22:59-65.
15. Inuyama Y, Kataura A, Togawa K, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Jpn J Cancer Chemother 1999;26:107-16.
16. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
17. Tominaga T, Ouchi K, Tanaka Y, et al. Schedule-dependency of antitumor activity in combination therapy with capecitabine/ doxifluridine and docetaxel in breast cancer models. Breast Cancer Res Treat 2000;64:86[342].
18. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Scheduledependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7:1079-86.
19. Fujimoto-Ouchi K, Yasuno H, Tanaka Y. Schedule-dependency of antitumor activity in combination therapy with capecitabine (Xeloda) and docetaxel in breast cancer models. AACR 2001;42: 463.